Speaker Spotlight

Dale Gerding, MD, FACP, FIDSA  — Thursday – Conference Chair
Dr. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position, Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious disease specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA) and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA.

Doctor Gerding will be the conference Chair on Thursday, November 7th  and a Key Note Speaker at the 7th Annual International C. diff. Conference and Health EXPO being hosted on
November 6-7 at the DoubleTree Westport – St. Louis, MO Hotel.

We went behind the scenes to ask Doctor Gerding a few questions that allow us to learn more about him on a personal, inspirational and professional level.

Doctor Gerding, what inspired you to become a Physician with a focus on  C. difficile? 
I was in charge of infection control at our hospital and when the new C  diff. test was put in by the lab we had so many positives that we thought the test was faulty. Turns our we were in the midst of a C, diff. outbreak and did not even realize it

What fuels your passion to continue striving for progress in your field?
I think we have the tools to prevent and treat C diff.  especially FMT, biotherapeutics, and non-toxigenic C  diff.  and I continue to work tirelessly (well maybe getting just a little tired) to see these agents available to patients to prevent primary CDI and recurrence’

Doctor Gerding, what is your big dream of what tomorrow looks like because of your work or with your work and the contributions of others?
My big dream is to see NTCD used with antibiotic therapy in the future and as a result wipe out virtually all cases of CDI, making it a non-issue for patients in the future.

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

Paul Feuerstadt, MD, FACG
Dr. Feuerstadt, MD, FACG,  is a Native of
Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training,
Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York-Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following the completion of his residency, Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training. His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr.Feuerstadt is affiliated with St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT.

Dr. Feuerstadt will be a Key Note Speaker on Wednesday, November 6th at
the 7th Annual International C. diff. Conference and Health EXPO being hosted on
November 6-7 at the DoubleTree Westport – St. Louis, MO Hotel.

We went behind the scenes to ask Doctor Feuerstadt a few questions that allow us to learn more about Doctor Feuerstadt on a personal, inspirational and professional level.

Doctor Feuerstadt, what inspired you to become a Physician?
I was inspired to be a physician by a motivation to help others and guide them through challenging times to health or comfort with their disease process. I gravitated toward C. difficile infection since I was fascinated by infectious disease, but chose a career in gastroenterology. This field was a bridge between both with fascinating epidemiology and an evolving landscape. In addition, we have treatments that cure C. difficile the overwhelming majority of the time which is very rewarding.

What fuels your passion to continue striving for progress in your field?
The evolution of this infection over the last 2 decades has been fascinating to watch. With the changes we have seen with the infection, we have also adapted medically with many new treatments and technologies to eradicate it. The ability to be at the forefront of management of CDI with next-generation antimicrobials (e.g., fidaxomicin), next-generation monoclonal antibodies (e.g., bezlotoxumab) and fecal microbiota transplantation has made this such an exciting disease to try to understand and contribute to the scientific fund of knowledge.

Dr. Feuerstadt, what is your big dream of what tomorrow looks like because of your work or with your work and the contributions of others?
The goal is to simplify the management of C. difficile infection and progress to single therapy eventually that will have a very high eradication rate with minimal recurrence.

Would you like to share a closing comment?
I am excited to be participating as a guest speaker at this year’s conference and
I look forward to meeting everyone there!